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Leiomyosarcoma is a malignant smooth muscle neoplasm with a complicated histopathologic classification scheme and marked
differences in clinical behavior depending on the anatomic site of origin. Overlapping morphologic features of benign and
borderline malignant smooth muscle neoplasms further complicate the diagnostic process. Likewise, deciphering the complex
and heterogeneous patterns of genetic changes which occur in this cancer has been challenging. Preliminary studies suggest
that reproducible molecular classification may be possible in the near future and new prognostic markers are emerging. Robust
recapitulation of leiomyosarcoma in mice with conditional deletion of Pten in smooth muscle and the simultaneous discovery of a
novel role for Pten in genomic stability provide a fresh perspective on the mechanism of leiomyosarcomagenesis and promise for
therapeutic intervention.
1. Introduction
Smooth muscle tumors constitute a spectrum of diseases
with wide-ranging clinical behaviors. In general, clinical
behavior correlates with patient age, tumor site, histologic
appearance, and stage. Leiomyosarcomas (LMSs), the malig-
nant variety, are less common than their benign counterpart,
leiomyomas (LMs), and most frequently occur in middle-
aged to elderly adults [1]. Children and adolescents generally
do not develop LM or LMS, and those rare neoplasms occur-
ring in this population are typically associated with Epstein
Barr virus expression, owing to an immunocompromised
state [1–3]. Excluding the extremely rare LMS of bone [3],
LMS represents approximately 24% of all sarcomas [4]
and is, therefore, one of the most common mesenchymal
malignancies. The two most frequent sites of origin are the
uterus and retroperitoneum, but LMS has been reported in
a variety of soft tissue sites, visceral organs, skin, and bone
[2, 3]. The diagnostic histopathologic features of smooth
muscle tumors are well defined [2]. Architecturally, LM
and well-differentiated LMS are composed of bundles and
fascicles of cells, intersecting at perpendicular angles. The
smooth muscle cells are typically elongate with abundant
eosinophilic cytoplasm, cigar-shaped nuclei, and perinuclear
vacuoles. Most well-differentiated lesions stain diffusely for
actins (smooth muscle actin or muscle-specific actin), and
many also stain for desmin, and h-caldesmon. These markers
are not specific for smooth muscle, however, and should
be interpreted in the context of appropriate clinical and
morphologic features. Up to 38% of LMSs will also stain
focally for cytokeratins [5], warranting careful discrimina-
tion from a sarcomatoid carcinoma and some synovial sar-
comas. Epithelioid forms of smooth muscle tumors occur
and demonstrate a strong staining pattern for actins, desmin,
and h-caldesmon similar to the spindle cell form.
The most widely accepted grading systems for LMS are
those defined for all soft tissue sarcomas by the United States
National Cancer Institute (NCI) and the French Fe´de´ration
Nationale des Centres de Lutte Contre le Cancer (FNCLCC)
[3]. Both consist of a three-grade scheme in which increasing
grade generally correlates with increasing tumor aggressive-
ness. The NCI system is based on histologic type, cellularity,
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nuclear atypia, mitotic count, and percent necrosis. Similarly,
the FNCLCC system is based on extent of differentiation,
mitotic count, and percent necrosis. For many soft tissue
sarcomas it is clear that histologic grade strongly predicts
outcome [6]. For LMS, however, grade is less predictive and
other factors such as neurovascular invasion appear to be
prognostic [6–8]. As tumors advance in grade, the obvious
morphologic features of smooth muscle and the char-
acteristic immunohistochemical staining can become less
prominent, rendering the diagnosis much more challenging.
But even well-differentiated smooth muscle tumors can pose
significant diagnostic challenges for pathologists. When the
full complement of malignant characteristics is lacking, our
current understanding of the appropriate classification for
predicting behavior is limited. Furthermore, the clinical
behavior of smooth muscle tumors is influenced by site of
origin, rendering the diagnostic process quite complex.
2. Clinicopathologic
Classification of Leiomyosarcoma
For prognostic purposes LMS should be subtyped based
on anatomic compartment of origin [1, 2]. Uterine LMS is
distinguished from soft tissue LMS, which refers to nonvis-
ceral tumors and includes cutaneous, major vessel, and deep
soft tissue [2]. The deep soft tissue tumors can be further
divided into retroperitoneal and somatic (peripheral). The
cutaneous variety behaves more like a benign tumor when it
is strictly limited to the dermis and is probably more aptly
termed atypical intradermal smooth muscle neoplasm [9].
Noncutaneous LMS, generally, is an aggressive neoplasm, but
noteworthy differences in biologic behavior exist among the
subtypes. In a large study of patients with soft tissue LMS
[10] the 5- and 10-year survival of subcutaneous LMS (83%
and 74%, resp.) was dramatically better than that of deeply-
seated tumors (50% and 39%). This same trend, in which the
superficial location of subcutaneous LMS predicts increased
survival over more deeply seated lesions, was observed in
a small study of somatic LMS [11]. The most common
form of deep soft tissue LMS arises in the retroperitoneum
and portends one of the worst prognoses for LMS. The
retroperitoneal tumors typically present as large masses
(>10 cm) with involvement of adjacent structures [1]. In
more recent retrospective analyses, the median survival time
has been reported as 24 months [12] and the overall 5-
year survival is less than 50% [13]. LMS of somatic soft
tissue has a slightly better prognosis and includes tumors
arising in the subcutis, soft tissues of the extremities, and
nonretroperitoneal/nonabdominopelvic tissues of the trunk
[1, 2, 14]. Given the varied origins of somatic tumors
it is reasonable to conclude that there will be additional
subtypes described as more studies accumulate. For example,
clinicopathologic studies of smooth muscle tumors arising
in the soft tissue of the external genitalia [14, 15] and the
inguinal region [16] have described unique features which
may lead to their distinction. Only very rarely LMS occurs in
these locations so it is difficult to ascertain the true behavior
of these tumors. It appears for now, though, that genital and
inguinal LMSs share some commonalities with other somatic
LMSs. For example, somatic LMS often presents at a smaller
size than those of the retroperitoneum but remains an
aggressive group with a reported 5- year survival rate of 64%
[8, 17]. Increasing tumor size, grade, and depth correlates
with decreased survival [8, 11, 17–20]. Increasing mitotic
index has also been shown to adversely affect prognosis
[20, 21], but this correlation has not been true in other
studies [8, 11, 17, 18]. Interestingly, at least one-quarter [11]
to one-third [17] of somatic LMSs originate from a vessel
wall but these lesions are distinguished from the major vessel
LMS group, which arises in large vessels, most commonly
the inferior vena cava (IVC) [22], have a worse prognosis,
and pose uniquely challenging clinical management issues.
Even with aggressive surgical resection the five-year survival
rate for LMS of the IVC has been reported to be between
33% and 68% [23–29]. A recent retrospective study of 40
LMSs of the IVC documented 5- and 10-year survival rates
of 50% and 22% [30]. The authors report that tumor grade
does not affect overall prognosis in amultivariate analysis but
impaired liver function correlated with the lowest overall sur-
vival. In addition, tumors with predominantly intraluminal
growth, incomplete resection, and suprahepatic location or
right atrial involvement correlate with death within 2 years.
While subtyping LMS by anatomic site is somewhat
helpful in predicting outcome, to fully appreciate the spec-
trum of disease and biologic potential of LMS it is useful
to understand that LMS resides on a morphologic and
behavioral continuum in which LM, intermediate lesions,
and LMS can have overlapping morphologic features. The
existence of benign lesions (LM) in deep soft tissue has been
controversial. In the last decade attempts have been made at
defining these tumors [15, 31], albeit with a healthy measure
of caution. The terminology for intermediate smooth mus-
cles tumors (with histopathologic features in between LM
and LMS) is complex, reflecting the fact that some of these
tumors recur and metastasize, and predicting their behavior
is challenging. Because these tumors are rare, there is limited
clinical data to correlate behavior with histopathologic fea-
tures. In addition, the diagnostic criteria for malignancy are
site-specific. Since the anatomic compartment helps predict
outcome, it is used to help distinguish benign, borderline,
and malignant lesions [2, 3, 14, 15, 31]. Borderline lesions
may be described with a variety of labels, including, but
not limited to, atypical leiomyoma, atypical leiomyoma with
potential for recurrence, smooth muscle tumor of uncertain
malignant potential, and the slightly more ominous, smooth
muscle tumor of low malignant potential. Criteria for malig-
nancy have been most extensively defined for uterine tumors
and consist of a detailed tiered system of weighted histologic
criteria including nuclear atypia, presence of coagulative
necrosis, and mitotic count [14]. For example, in the setting
of no more than mild nuclear atypia and no necrosis, a
proliferative index of greater than 9 mitoses per 10 high
powered fields (>9/10HPF) renders a borderline diagnostic
label and should warrant long-term clinical followup due
to the potential for recurrence and even metastasis. True
coagulative necrosis lowers the threshold of the minimum
mitotic count to <10/10HPF for a borderline tumor and
>/= 10/10HPF for LMS. In the absence of necrosis, overt
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atypia can render a borderline or malignant diagnosis only
when mitoses are present. Cytologic atypia and a mitotic
index of <10/10HPF yield a borderline diagnosis while a
mitotic count of >/= 10/10HPF bumps the diagnosis to
LMS. In the absence of mitoses and coagulative necrosis,
extremely bizarre nuclear features can occur in the setting of
a symplastic leiomyoma, now classified as atypical leiomyoma.
Atypical/symplastic LM is typically characterized by focal,
rather than diffuse, cytologic atypia. Importantly, the lack of
mitotic activity and necrosis distinguishes it from borderline
and malignant lesions. Strict adherence to the criteria for
histologic classification is necessary for appropriate diag-
nosis. Exceptions to these rules exist for nonconventional
(epithelioid and myxoid) uterine smooth muscle tumors but
are beyond the scope of this paper. Importantly, pathologists
must extensively sample smooth muscle tumors to avoid
erroneous diagnosis and subsequent inappropriate clinical
management.
Because nuclear atypia, mitotic count, and coagulation
necrosis have been useful features for stratifying risk in uter-
ine smooth muscle tumors, these criteria have been applied
to smooth muscle tumors from other anatomic locations.
As a result, site-specific diagnostic algorithms are emerging
[2, 14, 15, 31]. For example, retroperitoneal LM shares
many clinical and histopathologic features with uterine LM
and while mitotic index is frequently low (<1/50HPF) [32],
higher mitotic counts between 3 and 10/50HPF, in the ab-
sence of atypia and necrosis, have been reported with long-
term followup [31, 32]. These data suggest that similar to
uterine LM, mitotic activity alone may not indicate malig-
nancy [2]. Indeed, Hornick and Fletcher [15] have suggested
that mitotically active (<10/50HPF) uterine-type (estro-
gen/progesterone receptor positive by immunohistochemical
staining) smooth muscle tumors of the retroperitoneum
and abdomen in women are benign when necrosis and
significant atypia are absent. Likewise, vulvar and vaginal
smooth muscle tumors appear to have a good prognosis in
the setting of mild to moderate mitotic activity, and in some
cases, even with coexisting nuclear atypia [33–36]. While
these lesions may not have metastatic potential, some experts
have noted that any mitotic activity or atypia increases the
risk of local recurrence up to decades later [15]. Essentially
the threshold for definitive malignancy in a smooth muscle
tumor of the female external genitalia appears to be high, as
seen in the uterus. Hornick and Fletcher [15] define LMS
in this region as having at least 3 of 4 malignant features
including; (1) mitoses >5/10 HPF, (2) significant atypia, (3)
infiltrative margins, or (4) size >5 cm. Accordingly, tumors
meeting only 1-2 of the criteria are recommended for the
classification of “atypical smooth muscle tumor.” Another
potentially hormone-related LM of probable Mu¨llerian ori-
gin has recently been described in the inguinal region [16].
Again, low mitotic activity (0-6/10HPF) and mild atypia do
not appear to correlate with malignancy in the absence of
necrosis. In contrast, mitoses and atypia are significantly less
tolerated in smoothmuscle tumors of the male external geni-
talia [14, 15], deep soft tissue of the extremities [2, 14, 15, 31],
and retroperitoneal tumors in males [15]. In deep soft tissue,
including subcutaneous origin, some studies suggest that
any level of mitoses is worrisome for potential malignancy
[17, 37]. From these various studies it is clear that the only
criteria which are uniformly consistent with LM in deep soft
tissue are an absolute lack of mitoses, atypia, and necrosis. At
present the criteria are not absolute but it appears that any
deep soft tissue smooth muscle tumor demonstrating even
minimal mitoses or atypia may be reasonably classified as
atypical and afforded long-term followup.
3. Promising Discoveries
The challenge of classifying LMS with histopathologic cri-
teria and predicting outcome, as well as the poor survival
associated with this cancer, highlights the need for addi-
tional prognostic markers and identification of targets for
therapeutic intervention. A variety of approaches have been
undertaken which are beginning to provide some insight into
the biology of LMS. Recently, microRNA expression profiling
has resulted in successful distinction of uterine LMS from
LM and normal myometrium (n = 10 each) and revealed
that LMS has a more primitive, mesenchymal stem cell-
like microRNA population than LM [38]. Larger studies
will be necessary to determine how reliable and feasible this
technique is in distinguishing benign from intermediate and
malignant lesions. Within the malignant category, molecular
subclasses of LMS are beginning to emerge with the use
of RNA expression profiling [39, 40]. With a combined
approach of RNA expression profiling, array comparative
genomic hybridization (aCGH), and tissue array proteomics,
Beck and coauthors [40] identified novel prognostic markers
for LMS. The RNA expression array revealed three repro-
ducible clusters of gene expression, classified as groups I–
III. Group I showed enrichment of muscle-associated genes,
suggesting amore differentiated group of tumors. Expression
of these muscle-associated genes, detected in a large tissue
array of LMS samples (n = 124), predicted prolonged
survival. In contrast, expression of the macrophage colony
stimulating factor-1 (CSF-1) response pathway, previously
identified as a poor prognostic marker in breast cancer [41],
predicted poor outcome in the group III subclass of LMS [40,
42]. Although the authors did not report the mean survival
times to gauge the actual predicted survival advantage or
disadvantage, their results suggest these proteins may be use-
ful as potential prognostic biomarkers in LMS. Interestingly,
the aCGH analysis, completed in parallel, correlated closely
enough with the RNA expression array that aCGH was able
to predict groups I and III. This finding, along with the tissue
array data, provides confirmation that at least groups I and
III, as determined by RNA expression pattern, are probably
meaningful. The ability of the aCGH to align with the
expression array data also suggests that within what appears
to be uninterpretable chaos in LMS genomes, there may be
some hidden clues that hint at the etiology of this cancer.
Unlike the many sarcomas with recurrent chromosomal
alterations, LMS demonstrates highly complex, unstable kar-
yotypes (reviewed in [43]). A number of investigators have
attempted to find meaning in the complex cytogenetic
profiles of LMS and some commonalities have emerged.
Specifically, losses of the chromosome 13q and 10q, where
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the tumor suppressor genes retinoblastoma 1 (RB1) and
phosphatase and tensin homolog (Pten), respectively, reside,
are frequently reported alterations in LMS [40, 44–51]. Pten
point mutations have also been detected in LMS [52–54].
Pten alteration is a common finding in a variety of cancers
(reviewed in [55]). The Pten gene codes for a lipid and pro-
tein phosphatase that antagonizes the lipid kinase activity
of phosphatidylinositol 3-kinase (PI3K). Importantly, the
lipid phosphatase activity of Pten appears to be nonredun-
dant such that Pten loss consistently results in dysregu-
lation of PI3K, hyperactivation (phosphorylation) of Akt,
increased cellular proliferation, and inhibition of apoptosis.
PI3K/Akt signaling is facilitated by mammalian target of
rapamycin (mTOR), and hyperactivation of this pathway
in LMS has been repeatedly reported in human samples
[56–58] suggesting that markers such as phosphoAkt may
become useful in distinguishing benign from malignant neo-
plasms. Furthermore, immunohistochemical analysis of the
PI3K/Akt pathway activation state could help predict and
monitor treatment response and, therefore, guide therapeu-
tic decisions. Preliminary reports on clinical investigations
with mTOR inhibitors have shown some activity against
LMS. Specifically, one patient with metastatic uterine LMS
(out of eight patients with LMS) had a partial response
to temsirolimus sustained over 17 months [59]. In another
study with temsirolimus, three out of six patients with
LMS showed stable disease by RECIST criteria and a partial
response by the Choi criteria [60]. Deforolimus has also
shown promise. In a larger trial with 221 sarcoma patients,
ridaforolimus achieved a clinical benefit rate (defined as a
complete or partial response, or stable disease sustained for
16 weeks) of 29% [61]. Of the 57 LMS patients included in
this trial, those who received clinical benefit also showed an
improvement in overall survival by greater than five months.
While mTOR inhibitors show potential in the treatment
of LMS, the biology of this tumor suggests that mTOR
inhibitors will be most effective when used in combination
with other agents. Pten alterations in LMS, for example,
occur in the context of widespread genomic instability.
It is likely, therefore, that malignant smooth muscle cells
have achieved unregulated growth and metastatic potential
through a number of simultaneously functional mecha-
nisms. Molecular studies of human LMS and mouse mod-
els of LMS support this idea and may help explain the
stepwise progression of changes, involving Pten and other
cellular machinery, which lead to malignancy. Cytogenetic
studies of LMS have shown that high-grade tumors contain
significantly more DNA copy number gains while low-
grade tumors contain significantly more copy number losses,
suggesting that tumor suppressor loss may be an initiating
event and oncogene activation may occur later in malignant
progression [49]. DNA copy number gains also increase
with increasing tumor size [46] and specific sets of gains
are associated with only very large tumors [44]. In keeping
with the hypothesis that tumor suppressor loss is an early
event that precedes oncogene activation in leiomyosarcoma
genesis, Hernando and coauthors [56] reported that condi-
tional deletion of Pten in smooth muscle of mice results in
hyperactivated Akt signaling, rapid onset of smooth muscle
hyperplasia, and LMS. This animal model provides evidence
that smooth muscle cells are exquisitely sensitive to the
status of Pten function. The authors noted that while the
absence of Pten is necessary for tumor development, the
smooth muscle hyperplasia that also occurred in these mice,
a potential precursor lesion, suggests that Pten deficiency is
not sufficient for tumorigenesis. Additional steps required
for tumor formation may include p53 suppression. Indeed,
the authors report marked Mdm2 induction in the LMS
compared to the nonmalignant smooth muscle of the
Pten-null mice. They propose that activated Akt promotes
stabilization of Mdm2, thereby inactivating p53. The impli-
cation is that Pten loss, with subsequent hyperactivation of
PI3K/Akt, could pave the way for genomic instability. This is
a provocative concept which is supported by in vitro evidence
that Akt phosphorylates Mdm2, resulting in ubiquitination
and degradation of p53, and that when Pten is present to
inhibit Akt, p53 remains functional in mediating sensitivity
to DNA damaging agents (reviewed in [62]). Hence, Pten
loss may not only help initiate leiomyosarcomagenesis but
also contribute to genomic instability and chemoresistance.
On the other hand, inhibition of PI3K/Akt signaling, with
mTOR or PI3K inhibitors, may have the capacity to sensitize
cells to DNA damaging agents, but only in the setting of
intact p53 function. If intact p53 function is necessary to
achieve the anticancer effects of mTOR and PI3K inhibitors,
then careful selection of the appropriate patient population
may be warranted.
Shortly before the LMS phenotype was described in the
conditionally deleted Pten mouse, Shen and coauthors [63]
discovered a novel role for Pten in preserving chromosomal
integrity through a mechanism independent of its phos-
phatase activity and ability to regulate of PI3K/Akt signaling.
The discovery began with the observation that Pten-deficient
mouse embryonic fibroblasts spontaneously accumulate
a variety of chromosomal aberrations predominated by
centromeric breaks. Pten was then found to localize to
centromeres through an interaction with centromere binding
protein-C (CENP-C). CENP-C is necessary for kinetochore
function during mitosis and, therefore, enables appropriate
sister-chromatid segregation. Disruption of the interaction
of Pten with CENP-C, by either truncation of Pten or
point mutation within the C-terminus, leads to chromosome
instability. These Pten mutants were derived from known
germline mutations in Cowden syndrome patients, and the
authors demonstrated that Cowden syndrome lymphoblas-
toid cells, which are heterozygous for Pten mutation, exhibit
a high frequency of centromeric breaks. These compelling
data suggest that this form of mutant Pten, similar to TP53
gain of function mutants [64], can function as an oncogene,
rather than a tumor suppressor. In tumors, point mutations
in the N-terminal phosphatase domain of Pten are well doc-
umented and mutations in the C-terminal domain account
for approximately 40% of the reported mutations [65].
Pten dysfunction is potentially one of many mechanisms
contributing to the development of genomic instability in
LMS. Genomic instability is a major molecular feature of
LMS progression, and other genes have been implicated. For
example, TP53mutation has been documented in 24–39% of
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LMS [66, 67], is associated with higher-grade tumors [66],
and appears to be restricted to LMS because they do not
occur in LM [67]. In a recent study, Beck and coauthors [40]
showed frequent loss of chromosome 16q24 in a particular
molecular subset of LMS. This region harbors the Fanconi
anemia complementation group A (FANCA) gene, which
codes for one member of a large multiprotein complex that
coordinates with breast cancer, early onset (Brca) proteins in
the DNA damage signaling and repair process [68]. Xing and
coauthors [69] demonstrated that 29% (25 out of 85) uterine
LMSs show immunohistochemical loss of Brca1. In the
same study, conditional deletion of Brca1 in the developing
Mu¨llerian duct of themouse did not lead to tumor formation
but p53 deletion resulted in the development of malignant
smooth muscle tumors of the uterus. Concomitant deletion
of Brca1 and p53 resulted in a more accelerated phenotype.
Conditional deletion of p53 and Brca1 can also induce LMS
in the ovary [70]. Mdm2 amplification, an alternative means
of downregulating p53, has been reported in 14% of soft
tissue LMS [71, 72]. These data indicate a variety of mech-
anisms leading to DNA repair defects in LMS. Importantly,
new therapeutic agents which exploit DNA repair defects in
cancer cells have been developed.
The parallel discoveries of chromosome 16q24, FANCA
[40], and Brca1 [69] loss in LMS suggest defective double
strand break (DSB) repair and, therefore, potential vulner-
ability to poly (ADP-ribose) polymerase (PARP) inhibitors
(reviewed in [73]). PARP1 and PARP2 proteins are essen-
tial for the resolution of single-strand DNA breaks by the
base excision repair machinery. When PARP inhibitors are
employed in the context of defective DSB repair by homolo-
gous recombination (HR) repair mechanisms, such as with
Brca mutation, cells become extremely sensitive to DNA
damaging agents. PARP inhibitors create synthetic lethality
in this situation by shutting down a second mechanism of
DNA repair. Interestingly, Pten has been linked to DSB repair
by regulating the expression of RAD51, a HR repair protein,
and Pten loss is associated with defective DSB repair [63, 74].
Furthermore, PARP inhibitors generate synthetic lethality in
Pten-deficient tumors [74–76]. These data suggest that in
subsets of LMS with DSB repair defects, which may include
Pten deficiency, PARP inhibitors may be able to sensitize
these tumors to DNA damaging agents.
4. Conclusions
The era of personalized cancer medicine has begun, and
recent advancements in our understanding of LMS indicate
that tailored therapy for this disease is in sight. Molecular and
proteomic analysis is beginning to uncover biomarkers which
may improve our ability to classify smooth muscle tumors
and predict clinical outcome. Furthermore, the parallel and
profound discoveries that Pten is a critical guardian of
genomic integrity and initiator of LMS in mice provide a
mechanism of tumorigenesis and potential Achilles heel. The
high frequency of Pten alteration in cancer, together with
its role in genomic stability and synthetic lethal relationship
with PARP inhibition, suggests that PARP inhibitors may
find widespread use as anticancer agents [73], including in
LMS. Screening for alterations in Pten and other genes which
regulate or directly participate in DSB repair may help guide
the use of PARP inhibitors in LMS and other cancers. In
fact, as new classes of DNA repair inhibitors emerge, the
need may eventually arise to evaluate the entire cellular
DNA damage response machinery in every tumor subject
to systemic treatment. Likewise, the effectiveness of mTOR
and PI3K inhibitors may be dependent on TP53 status. A
complete evaluation of Pten and TP53 is notoriously labor
intensive due to the wide variety of mechanisms by which
these genes can be altered. One of the challenges in the future
of personalized cancer care will be to develop appropriate,
reliable, and affordable laboratory-based clinical tests with
reasonable turn-around times. We are optimistic this is an
achievable goal with next-generation sequencing approaches
to molecular profiling. Emerging molecular technologies
may also help reveal new insights into the biology of LMS
and improve the effectiveness of therapeutic intervention.
Acknowledgment
The authors thank Aubrey C. Chan for careful editing of this
paper.
References
[1] S. W. Weiss and J. Goldblum, Enzinger and Weiss’s Soft Tissue
Tumors, Elsevier, Philadelphia, Pa, USA, 2007.
[2] S. W. Weiss, “Smooth muscle tumors of soft tissue,” Advances
in Anatomic Pathology, vol. 9, no. 6, pp. 351–359, 2002.
[3] C. D. M. Fletcher, K. K. Unni, and F. Mertens, Pathology and
Genetics of Tumours of Soft Tissue and Bone, IARC Press, Lyon,
France, 2002.
[4] J. R. Toro, L. B. Travis, J. W. Hongyu, K. Zhu, C. D.M. Fletcher,
and S. S. Devesa, “Incidence patterns of soft tissue sarcomas,
regardless of primary site, in the Surveillance, Epidemiology
and End Results program, 1978–2001: an analysis of 26,758
cases,” International Journal of Cancer, vol. 119, no. 12, pp.
2922–2930, 2006.
[5] J. Iwata and C. D. M. Fletcher, “Immunohistochemical detec-
tion of cytokeratin and epithelial membrane antigen in lei-
omyosarcoma: a systematic study of 100 cases,” Pathology In-
ternational, vol. 50, no. 1, pp. 7–14, 2000.
[6] J. M. Coindre, P. Terrier, L. Guillou et al., “Predictive value of
grade for metastasis development in the main histologic types
of adult soft tissue sarcomas: a study of 1240 patients from the
French Federation of Cancer Centers sarcoma group,” Cancer,
vol. 91, no. 10, pp. 1914–1926, 2001.
[7] P. Gustafson, K. E. Dreinhofer, and A. Rydholm, “Soft tissue
sarcoma should be treated at a tumor center: a comparison
of quality of surgery in 375 patients,” Acta Orthopaedica Scan-
dinavica, vol. 65, no. 1, pp. 47–50, 1994.
[8] P. Gustafson, H. Willen, B. Baldetorp, M. Ferno, M. Akerman,
and A. Rydholm, “Soft tissue leiomyosarcoma: a population-
based epidemiologic and prognostic study of 48 patients, in-
cluding cellular DNA content,” Cancer, vol. 70, no. 1, pp. 114–
119, 1992.
[9] S. Kraft and C. D. M. Fletcher, “Atypical intradermal smooth
muscle neoplasms: clinicopathologic analysis of 84 cases and
a reappraisal of cutaneous ‘leiomyosarcoma’,” American Jour-
nal of Surgical Pathology, vol. 35, no. 4, pp. 599–607, 2011.
6 Sarcoma
[10] C. Svarvar, T. Bohling, O. Berlin et al., “Clinical course of non-
visceral soft tissue leiomyosarcoma in 225 patients from the
scandinavian sarcoma group,” Cancer, vol. 109, no. 2, pp. 282–
291, 2007.
[11] H. Hashimoto, Y. Daimaru, M. Tsuneyoshi, and M. Enjoji,
“Leiomyosarcoma of the external soft tissues. A clinicopatho-
logic, immunohistochemical, and electronmicroscopic study,”
Cancer, vol. 57, no. 10, pp. 2077–2088, 1986.
[12] N. Bautista, W. Su, and T. X. O’Connell, “Retroperitoneal soft-
tissue sarcomas: prognosis and treatment of primary and re-
current disease,”American Surgeon, vol. 66, no. 9, pp. 832–836,
2000.
[13] E. Stoeckle, J. M. Coindre, S. Bonvalot et al., “Prognostic fac-
tors in retroperitoneal sarcoma: a multivariate analysis of a
series of 165 patients of the French Cancer Center Federation
Sarcoma Group,” Cancer, vol. 92, no. 2, pp. 359–368, 2001.
[14] M. Miettinen and J. F. Fetsch, “Evaluation of biological poten-
tial of smooth muscle tumours,” Histopathology, vol. 48, no. 1,
pp. 97–105, 2006.
[15] J. L. Hornick and C. D. M. Fletcher, “Criteria for malignancy
in nonvisceral smooth muscle tumors,” Annals of Diagnostic
Pathology, vol. 7, no. 1, pp. 60–66, 2003.
[16] D. T. Patil, W. B. Laskin, J. F. Fetsch, and M. Miettinen,
“Inguinal smooth muscle tumors in women-a dichotomous
group consisting of mu¨llerian-type leiomyomas and soft tissue
leiomyosarcomas: an analysis of 55 cases,” American Journal of
Surgical Pathology, vol. 35, no. 3, pp. 315–324, 2011.
[17] G. Farshid, M. Pradhan, J. Goldblum, and S. W. Weiss, “Lei-
omyosarcoma of somatic soft tissues: a tumor of vascular ori-
gin with multivariate analysis of outcome in 42 cases,” Amer-
ican Journal of Surgical Pathology, vol. 26, no. 1, pp. 14–24,
2002.
[18] A. G. Wile, H. L. Evans, and M. M. Romsdahl, “Leiomyosar-
coma of soft tissue: a clinicopathologic study,” Cancer, vol. 48,
no. 4, pp. 1022–1032, 1981.
[19] A. I. Neugut and P. P. Sordillo, “Leiomyosarcomas of the ex-
tremities,” Journal of Surgical Oncology, vol. 40, no. 1, pp. 65–
67, 1989.
[20] K. Miyajima, Y. Oda, Y. Oshiro et al., “Clinicopathological
prognostic factors in soft tissue leiomyosarcoma: a multivari-
ate analysis,” Histopathology, vol. 40, no. 4, pp. 353–359, 2002.
[21] D. Massi, G. Beltrami, M. M. Mela, M. Pertici, R. Capanna,
and A. Franchi, “Prognostic factors in soft tissue leiomyosar-
coma of the extremities: a retrospective analysis of 42 cases,”
European Journal of Surgical Oncology, vol. 30, no. 5, pp. 565–
572, 2004.
[22] J. Kevorkian and D. P. Cento, “Leiomyosarcoma of large arter-
ies and veins,” Surgery, vol. 73, no. 3, pp. 390–400, 1973.
[23] J. Dew, K. Hansen, J. Hammon, T. McCoy, E. A. Levine, and
P. Shen, “Leiomyosarcoma of the inferior vena cava: surgical
management and clinical results,” American Surgeon, vol. 71,
no. 6, pp. 497–501, 2005.
[24] O. J. Hines, S. Nelson, W. J. Quinones-Baldrich, and F. R.
Eilber, “Leiomyosarcoma of the inferior vena cava: prognosis
and comparison with leiomyosarcoma of other anatomic
sites,” Cancer, vol. 85, no. 5, pp. 1077–1083, 1999.
[25] S. T. Hollenbeck, S. R. Grobmyer, K. C. Kent, and M. F. Bren-
nan, “Surgical treatment and outcomes of patients with pri-
mary inferior vena cava leiomyosarcoma,” Journal of the Amer-
ican College of Surgeons, vol. 197, no. 4, pp. 575–579, 2003.
[26] H. Ito, J. L. Hornick, M. M. Bertagnolli et al., “Leiomyosar-
coma of the inferior vena cava: survival after aggressive man-
agement,” Annals of Surgical Oncology, vol. 14, no. 12, pp.
3534–3541, 2007.
[27] E. Kieffer, M. Alaoui, J. C. Piette, P. Cacoub, and L. Chiche,
“Leiomyosarcoma of the inferior vena cava: experience in 22
cases,” Annals of Surgery, vol. 244, no. 2, pp. 289–295, 2006.
[28] A. Mingoli, A. Cavallaro, P. Sapienza, L. Di Marzo, R. J.
Feldhaus, and N. Cavallari, “International Registry of Inferior
Vena Cava Leiomyosarcoma: analysis of a world series on 218
patients,” Anticancer Research, vol. 16, no. 5, pp. 3201–3205,
1996.
[29] G. Illuminati, F. G. Calio’, A. D’Urso, D. Giacobbi, V. Papas-
pyropoulos, and G. Ceccanei, “Prosthetic replacement of the
infrahepatic inferior vena cava for leiomyosarcoma,” Archives
of Surgery, vol. 141, no. 9, pp. 919–924, 2006.
[30] W. B. Laskin, J. C. Fanburg-Smith, A. P. Burke, E. Kraszewska,
J. F. Fetsch, and M. Miettinen, “Leiomyosarcoma of the infer-
ior vena cava: clinicopathologic study of 40 cases,” American
Journal of Surgical Pathology, vol. 34, no. 6, pp. 873–881, 2010.
[31] S. D. Billings, A. L. Folpe, and S. W. Weiss, “Do leiomyomas
of deep soft tissue exist? An analysis of highly differentiated
smooth muscle tumors of deep soft tissue supporting two dis-
tinct subtypes,” American Journal of Surgical Pathology, vol. 25,
no. 9, pp. 1134–1142, 2001.
[32] E. Paal and M. Miettinen, “Retroperitoneal leiomyomas:
a clinicopathologic and immunohistochemical study of 56
cases with a comparison to retroperitoneal leiomyosarcomas,”
American Journal of Surgical Pathology, vol. 25, no. 11, pp.
1355–1363, 2001.
[33] U. N. M. Rao, S. D. Finkelstein, and M. W. Jones, “Compara-
tive immunohistochemical and molecular analysis of uterine
and extrauterine leiomyosarcomas,” Modern Pathology, vol.
12, no. 11, pp. 1001–1009, 1999.
[34] F. A. Tavassoli and H. J. Norris, “Smooth muscle tumors of the
vagina,” Obstetrics and Gynecology, vol. 53, no. 6, pp. 689–693,
1979.
[35] F. A. Tavassoli and H. J. Norris, “Smooth muscle tumors of the
vulva,” Obstetrics and Gynecology, vol. 53, no. 2, pp. 213–217,
1979.
[36] G. P. Nielsen, A. E. Rosenberg, F. C. Koerner, R. H. Young, and
R. E. Scully, “Smooth-muscle tumors of the vulva: a clinico-
pathological study of 25 cases and review of the literature,”
American Journal of Surgical Pathology, vol. 20, no. 7, pp. 779–
793, 1996.
[37] C. D. M. Fletcher, S. E. Kilpatrick, and T. Mentzel, “The
difficulty in predicting behavior of smooth-muscle tumors in
deep soft tissue,” American Journal of Surgical Pathology, vol.
19, no. 1, pp. 116–117, 1995.
[38] L. S. Danielson, S. Menendez, C. S. O. Attolini et al., “A
differentiation-based microRNA signature identifies leiom-
yosarcoma as a mesenchymal stem cell-related malignancy,”
American Journal of Pathology, vol. 177, no. 2, pp. 908–917,
2010.
[39] P. Francis, H. M. Namløs, C. Mu¨ller et al., “Diagnostic and
prognostic gene expression signatures in 177 soft tissue sar-
comas: hypoxia-induced transcription profile signifies meta-
static potential,” BMC Genomics, vol. 8, article 73, 2007.
[40] A. H. Beck, C. H. Lee, D. M. Witten et al., “Discovery of
molecular subtypes in leiomyosarcoma through integrative
molecular profiling,” Oncogene, vol. 29, no. 6, pp. 845–854,
2010.
[41] A. H. Beck, I. Espinosa, B. Edris et al., “The macrophage
colony-stimulating factor 1 response signature in breast carci-
noma,” Clinical Cancer Research, vol. 15, no. 3, pp. 778–787,
2009.
[42] I. Espinosa, A. H. Beck, C. H. Lee et al., “Coordinate expres-
sion of colony-stimulating factor-1 and colony-stimulating
Sarcoma 7
factor-1-related proteins is associated with poor prognosis in
gynecological and nongynecological leiomyosarcoma,” Amer-
ican Journal of Pathology, vol. 174, no. 6, pp. 2347–2356, 2009.
[43] J. Yang, X. Du, K. Chen et al., “Genetic aberrations in soft
tissue leiomyosarcoma,”Cancer Letters, vol. 275, no. 1, pp. 1–8,
2009.
[44] W. El-Rifai, M. Sarlomo-Rikala, S. Knuutila, and M. Mietti-
nen, “DNA copy number changes in development and prog-
ression in leiomyosarcomas of soft tissues,” American Journal
of Pathology, vol. 153, no. 3, pp. 985–990, 1998.
[45] M. Otan˜o-Joos, G.Mechtersheimer, S. Ohl et al., “Detection of
chromosomal imbalances in leiomyosarcoma by comparative
genomic hybridization and interphase cytogenetics,” Cytoge-
netics and Cell Genetics, vol. 90, no. 1-2, pp. 86–92, 2000.
[46] R. Wang, Y. J. Lu, C. Fisher, J. A. Bridge, and J. Shipley,
“Characterization of chromosome aberrations associated with
soft-tissue leiomyosarcomas by twenty-four-color karyotyp-
ing and comparative genomic hybridization analysis,” Genes
Chromosomes and Cancer, vol. 31, no. 1, pp. 54–64, 2001.
[47] J. Lee, S. Li, M. Torbenson et al., “Leiomyosarcoma of the
breast: a pathologic and comparative genomic hybridization
study of two cases,” Cancer Genetics and Cytogenetics, vol. 149,
no. 1, pp. 53–57, 2004.
[48] J. Hu, U. N. M. Rao, S. Jasani, V. Khanna, K. Yaw, and U. Surti,
“Loss of DNA copy number of 10q is associated with aggressive
behavior of leiomyosarcomas: a comparative genomic hybrid-
ization study,” Cancer Genetics and Cytogenetics, vol. 161, no.
1, pp. 20–27, 2005.
[49] M. L. Larramendy, S. Kaur, C. Svarvar, T. Bohling, and S.
Knuutila, “Gene copy number profiling of soft-tissue leiomyo-
sarcomas by array-comparative genomic hybridization,” Can-
cer Genetics and Cytogenetics, vol. 169, no. 2, pp. 94–101, 2006.
[50] C. Giacinti and A. Giordano, “RB and cell cycle progression,”
Oncogene, vol. 25, no. 38, pp. 5220–5227, 2006.
[51] L. A. Meza-Zepeda, S. H. Kresse, A. H. Barragan-Polania et
al., “Array comparative genomic hybridization reveals distinct
DNA copy number differences between gastrointestinal stro-
mal tumors and leiomyosarcomas,” Cancer Research, vol. 66,
no. 18, pp. 8984–8993, 2006.
[52] F. Amant, M. de la Rey, C.M. Dorfling et al., “PTENmutations
in uterine sarcomas,” Gynecologic Oncology, vol. 85, no. 1, pp.
165–169, 2002.
[53] T. Saito, Y. Oda, K. I. Kawaguchi et al., “PTEN/MMAC1 gene
mutation is a rare event in soft tissue sarcomas without specific
balanced translocations,” International Journal of Cancer, vol.
104, no. 2, pp. 175–178, 2003.
[54] K. I. Kawaguchi, Y. Oda, T. Saito et al., “Genetic and epigenetic
alterations of the PTEN gene in soft tissue sarcomas,” Human
Pathology, vol. 36, no. 4, pp. 357–363, 2005.
[55] S. Zhang and D. Yu, “PI(3)king apart PTEN’s role in cancer,”
Clinical Cancer Research, vol. 16, no. 17, pp. 4325–4330, 2010.
[56] E. Hernando, E. Charytonowicz, M. E. Dudas et al., “The
AKT-mTOR pathway plays a critical role in the development
of leiomyosarcomas,” Nature Medicine, vol. 13, no. 6, pp. 748–
753, 2007.
[57] S. Dhingra, M. E. Rodriguez, Q. Shen et al., “Constitutive acti-
vation with overexpression of themTORC2-phospholipase D1
pathway in uterine leiomyosarcoma and STUMP:morphopro-
teomic analysis with therapeutic implications,” International
Journal of Clinical and Experimental Pathology, vol. 4, no. 2,
pp. 134–146, 2011.
[58] G. Garg, A. Short, J. R. Liu et al., “Akt-mTOR pathway in
uterine leiomyosarcoma,” Journal of Clinical Oncology, vol. 29,
2011, abstract no. 5040.
[59] S. Okuno, H. Bailey, M. R. Mahoney et al., “A phase 2 study of
temsirolimus (CCI-779) in patients with soft tissue sarcomas:
a study of the mayo phase 2 Consortium (P2C),” Cancer, vol.
117, no. 15, pp. 3468–3475, 2011.
[60] A. Italiano, M. Kind, E. Stoeckle, N. Jones, J.-M. Coindre,
and B. Bui, “Temsirolimus in advanced leiomyosarcomas: pat-
terns of response and correlation with the activation of the
mammalian target of rapamycin pathway,” Anti-Cancer Drugs,
vol. 22, no. 5, pp. 463–467, 2011.
[61] S. P. Chawla, A. W. Tolcher, A. P. Staddon et al., “Survival
results with AP23573, a novel mTOR inhibitor, in patients
(pts) with advanced soft tissue or bone sarcomas: update of
phase II trial,” Journal of Clinical Oncology, vol. 25, no. 18S,
2007, abstract no. 10076.
[62] D. W. Meek and U. Knippschild, “Posttranslational modifica-
tion of MDM2,” Molecular Cancer Research, vol. 1, no. 14, pp.
1017–1026, 2003.
[63] W. H. Shen, A. S. Balajee, J. Wang et al., “Essential role for
nuclear PTEN in maintaining chromosomal integrity,” Cell,
vol. 128, no. 1, pp. 157–170, 2007.
[64] A. J. Levine, M. C. Wu, A. Chang et al., “The spectrum of mu-
tations at the p53 locus,” Annals of the New York Academy of
Sciences, vol. 768, pp. 111–128, 1995.
[65] K. A. Waite and C. Eng, “Protean PTEN: form and function,”
American Journal of Human Genetics, vol. 70, no. 4, pp. 829–
844, 2002.
[66] K. I. Kawaguchi, Y. Oda, T. Saito et al., “Death-associated pro-
tein kinase (DAP kinase) alteration in soft tissue leiomyosar-
coma: promoter methylation or homozygous deletion is as-
sociated with a loss of DAP kinase expression,” Human Path-
ology, vol. 35, no. 10, pp. 1266–1271, 2004.
[67] M. Ito, L. Barys, T. O’Reilly et al., “Comprehensive mapping
of p53 pathway alterations reveals an apparent role for both
SNP309 and MDM2 amplification in sarcomagenesis,” Clini-
cal Cancer Research, vol. 17, no. 3, pp. 416–426, 2011.
[68] W. Wang, “Emergence of a DNA-damage response network
consisting of Fanconi anaemia and BRCA proteins,” Nature
Reviews Genetics, vol. 8, no. 10, pp. 735–748, 2007.
[69] D. Xing, G. Scangas, M. Nitta et al., “A role for BRCA1 in
uterine leiomyosarcoma,” Cancer Research, vol. 69, no. 21, pp.
8231–8235, 2009.
[70] B. A. Quinn, T. Brake, X. Hua et al., “Induction of ovarian
leiomyosarcomas in mice by conditional inactivation of Brca1
and p53,” PLoS One, vol. 4, no. 12, Article ID e8404, 2009.
[71] H. Taubert, K. Schuster, U. Brinck et al., “Loss of heterozygos-
ity at 12q14-15 often occurs in stage I soft tissue sarcomas and
is associated with MDM2 amplification in tumors at various
stages,” Modern Pathology, vol. 16, no. 11, pp. 1109–1116,
2003.
[72] P. Ragazzini, G. Gamberi, L. Pazzaglia et al., “Amplification
of CDK4, MDM2, SAS and GLI genes in leiomyosarcoma,
alveolar and embryonal rhabdomyosarcoma,” Histology and
Histopathology, vol. 19, no. 2, pp. 401–411, 2004.
[73] T. A. Yap, S. K. Sandhu, C. P. Carden, and J. S. De Bono,
“Poly (ADP-ribose) polymerase (PARP) inhibitors: exploiting
a synthetic lethal strategy in the clinic,” CA Cancer Journal for
Clinicians, vol. 61, no. 1, pp. 31–49, 2011.
[74] A. M. Mendes-Pereira, S. A. Martin, R. Brough et al., “Syn-
thetic lethal targeting of PTEN mutant cells with PARP inhi-
bitors,” EMBO Molecular Medicine, vol. 1, no. 6-7, pp. 315–
322, 2009.
[75] B. McEllin, C. V. Camacho, B. Mukherjee et al., “PTEN loss
compromises homologous recombination repair in astrocytes:
implications for glioblastoma therapy with temozolomide or
8 Sarcoma
poly(ADP-Ribose) polymerase inhibitors,” Cancer Research,
vol. 70, no. 13, pp. 5457–5464, 2010.
[76] K. J. Dedes, D. Wetterskog, A. M. Mendes-Pereira et al.,
“Preclinical evaluation of PARP inhibition as a treatment for
endometrioid endometrial carcinomas,” Journal of Clinical
Oncology, vol. 28, no. 15s, 2010, abstract no. 5065.
